Hereditary Angioedema Clinical Trials Analysis 2025: Novel Therapeutics, Prophylactic Agents, and Gene-Targeted Approaches Aim to Reduce Attacks and Improve Quality of Life | DelveInsight

DelveInsight's "Hereditary Angioedema (HAE) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline designed to prevent and manage acute HAE attacks. Despite available C1-INH replacement therapies and bradykinin receptor antagonists, patients continue to face unpredictable, sometimes life-threatening attacks, emphasizing the need for more effective and convenient treatment options.

The HAE pipeline is progressing with next-generation C1-INH formulations, oral kallikrein inhibitors, and gene-targeted therapies that aim for long-term prophylaxis. Combination approaches and improved delivery systems are being explored to enhance patient convenience and adherence. Emerging small molecules and biologics are also under investigation to provide a faster onset of action and reduce attack frequency.

Clinical trials increasingly focus on patient-reported outcomes, attack frequency, severity reduction, and safety profiles to capture both efficacy and quality-of-life improvements. With several late-stage candidates advancing globally, the HAE treatment landscape is poised to become more personalized, offering patients safer, more effective, and easier-to-administer therapies.

Curious about the latest breakthroughs in hereditary angioedema treatment? Discover cutting-edge drugs and the evolving pipeline-click here to explore: https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Hereditary Angioedema Pipeline Report
• DelveInsight's Hereditary Angioedema Pipeline analysis depicts a robust space with 20+ active players working to develop 30+ pipeline drugs for Hereditary Angioedema treatment.
• The leading Hereditary Angioedema companies include BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, and others are evaluating their lead assets to improve the Hereditary Angioedema treatment landscape.
• Key Hereditary Angioedema pipeline therapies in various stages of development include BCX7353, KVD900, PHA121, BMN 331, IONIS-PKK-LRx, NTLA-2002, and others.
• In September 2025, following FDA approval of Dawnzera (donidalorsen) for hereditary angioedema (HAE), Piper Sandler reaffirmed an Overweight rating on Ionis Pharmaceuticals and raised its price target to $65, highlighting the company's strong sales team and potential in the competitive HAE market.
• In August 2025, Ionis Pharmaceuticals (NASDAQ: IONS) announced FDA approval of Dawnzera (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older. Dawnzera is the first RNA-targeted therapy for HAE, designed to inhibit plasma prekallikrein (PKK), a key trigger of inflammatory attacks.
• In July 2025, KalVista Pharmaceuticals announced FDA approval of EKTERLY® (sebetralstat), the first oral on-demand treatment for acute hereditary angioedema (HAE) attacks in patients aged 12 and older. EKTERLY offers rapid symptom relief and could transform HAE management as the first new on-demand therapy in over a decade.
• In June 2025, BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced new long-term efficacy and safety data for ORLADEYO® (berotralstat), used as prophylactic treatment for hereditary angioedema (HAE) in patients of all ages.
• In June 2025, the FDA approved CSL's AndembryTM (garadacimab-gxii) for preventing hereditary angioedema (HAE) attacks in patients 12 and older. Phase III trial results showed a 99% reduction in monthly attacks, with 62% of patients attack-free for six months.
• In June 2025, CSL announced FDA approval of ANDEMBRY® (garadacimab-gxii), the first once-monthly subcutaneous treatment targeting factor XIIa to prevent hereditary angioedema (HAE) attacks in patients aged 12 and older.
• In June 2025, KalVista Pharmaceuticals announced that the FDA will miss the June 17 PDUFA goal date for its NDA review of sebetralstat, an oral on-demand treatment for hereditary angioedema, due to workload constraints. A decision is expected within about four weeks.
• In January 2025, Intellia Therapeutics, Inc. announced dosing of the first patient in its global Phase III trial of NTLA-2002 for Hereditary Angioedema (HAE). NTLA-2002 is an investigational in vivo, single-dose CRISPR therapy designed to treat this life-threatening condition. The company expects to complete enrollment by H2 2025 and aims to file a Biologics License Application (BLA) in 2026, targeting a potential U.S. launch in 2027.

Request a sample and discover the recent breakthroughs happening in the Hereditary Angioedema pipeline landscape @ https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hereditary Angioedema Overview
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent, severe swelling episodes affecting the limbs, face, gastrointestinal tract, and airways. Attacks may be triggered by stress or injury, but often occur without a clear cause. Gastrointestinal episodes can cause intense abdominal pain, while airway swelling can be life-threatening. About one-third of patients may develop a non-itchy rash (erythema marginatum). Symptoms usually begin in childhood and worsen at puberty. Without treatment, attacks typically occur every 1-2 weeks, last 3-4 days, and vary widely in frequency and severity, even within families.

Find out more about Hereditary Angioedema medication @ https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hereditary Angioedema Treatment Analysis: Drug Profile
KVD900 - KalVista Pharmaceuticals
KVD900 is an oral plasma kallikrein inhibitor developed by KalVista Pharmaceuticals, designed specifically for the on-demand treatment of hereditary angioedema (HAE) attacks. It boasts high solubility, excellent permeability, and rapid plasma uptake, allowing for quick and effective symptom control. KVD900 is currently in Phase III clinical trials for HAE.

PHA121 - Pharvaris
PHA121 is an innovative small-molecule B2 receptor antagonist being developed by Pharvaris. It has shown strong potency and selectivity in preclinical studies, effectively targeting bradykinin pathways involved in HAE. The drug is currently advancing through Phase II clinical trials for hereditary angioedema.

Learn more about the novel and emerging Hereditary Angioedema pipeline therapies @ https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Hereditary Angioedema Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical

By Molecule Type
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

Scope of the Hereditary Angioedema Pipeline Report
• Coverage: Global
• Key Hereditary Angioedema Companies: BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, and others.
• Key Hereditary Angioedema Pipeline Therapies: BCX7353, KVD900, PHA121, BMN 331, IONIS-PKK-LRx, NTLA-2002, and others.

Dive deep into rich insights for drugs used for Hereditary Angioedema treatment; visit @ https://www.delveinsight.com/report-store/hereditary-angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Hereditary Angioedema Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Hereditary Angioedema Pipeline Therapeutics
6. Hereditary Angioedema Pipeline: Late-Stage Products (Phase III)
7. Hereditary Angioedema Pipeline: Late-Stage Products (Phase III)
8. Hereditary Angioedema Pipeline: Mid-Stage Products (Phase II)
9. Hereditary Angioedema Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.